Ultragenyx Pharmaceutical Inc (RARE)

Etorro trading 970x250
Ultragenyx Pharmaceutical Inc (RARE) Logo

About Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California. Address: 60 Leveroni Court, Novato, CA, United States, 94949

Ultragenyx Pharmaceutical Inc News and around…

Latest news about Ultragenyx Pharmaceutical Inc (RARE) common stock and company :

Peek Under The Hood: IWS Has 11% Upside
19 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell Mid-Cap Value ETF (IWS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $134.41 per unit.

4 Beaten-Down Biotech Stocks That Could Take Off
17 Nov, 2021 Yahoo! Finance

The S&P 500 is up about 25% so far this year, but key biotech exchange-traded funds are lagging far behind.

Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates
03 Nov, 2021 Yahoo! Finance

Ultragenyx (RARE) reports narrower-than-expected loss in the third quarter of 2021 while revenues surpass estimates.

Ultragenyx Pharmaceutical inc (RARE) Q3 2021 Earnings Call Transcript
03 Nov, 2021 FinancialContent

RARE earnings call for the period ending October 2, 2021.

Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
02 Nov, 2021 Yahoo! Finance

Ultragenyx (RARE) delivered earnings and revenue surprises of 24.48% and 4.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update
02 Nov, 2021 Yahoo! Finance

Third quarter 2021 total revenue of $81.6 million including Crysvita1 revenue to Ultragenyx of $50.3 million 2021 Crysvita revenue in Ultragenyx territories1 now expected towards the upper end of the$180 million to $190 million range previously provided NOVATO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, tod

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
02 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst ...

Earnings Scheduled For November 2, 2021
02 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per ...

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct, 2021 FinancialContent

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly ...

Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corporate Update
26 Oct, 2021 Yahoo! Finance

NOVATO, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, November 2, 2021 at 5pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2021. The live and replayed webcast of the call will be available through the company’s website at

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit
25 Oct, 2021 Yahoo! Finance

NOVATO, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Gene Therapy/Editing Summit on October 28, 2021 at 3:30 PM ET. The live and archived webcast of the presentation will be acc

Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline
19 Oct, 2021 Yahoo! Finance

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hedge Funds Are Piling Into Ultragenyx Pharmaceutical Inc (RARE)
18 Oct, 2021 Yahoo! Finance

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
18 Oct, 2021 Yahoo! Finance

NOVATO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare genetic diseases, today announced that it has successfully screened and enrolled multiple patients with Wilson disease into the baseline monitoring period prior to dosing in its pivotal, seamless Phase 1/2/3 study of UX701, the Cyprus2+ study. The company's investigational AAV9 gene

Ultragenyx Pharmaceutical Insider Sold $550K In Company Stock
15 Oct, 2021 Yahoo! Finance

Mardi Dier, CFO And Executive Vice President at Ultragenyx Pharmaceutical (NASDAQ:RARE), made a large insider sell on October 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Dier sold 6,738 shares of Ultragenyx Pharmaceutical at prices ranging from $81.16 to $82.79. The total transaction amounted to $552,524. Following the transaction, Dier still owns 38,762 shares of the company, worth $3,127,705. Ultrage

Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada
08 Oct, 2021 Yahoo! Finance

Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.

GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
07 Oct, 2021 Yahoo! Finance

SARASOTA, Fla. and NOVATO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, today announced that the first patient has been dosed in the Phase 1/2 study in Canada with three other patients enrolled and scheduled to begin dosing. “We have been actively working with our principal investigators across all three regions over the

Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
01 Oct, 2021 Yahoo! Finance

Previously reported data demonstrated dose-dependent, statistically significant bone-building effect at multiple anatomical sites in adult patients with OI that was consistent across subtypes of OI Dose-dependent improvements in serum biomarkers of bone turnover with UX143 therapy confirm sclerostin inhibition mechanism of action LONDON and NOVATO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and c

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
30 Sep, 2021 FinancialContent

Over the past 3 months, 4 analysts have published their opinion on Ultragenyx Pharmaceutical (NASDAQ:RARE) stock. These analysts are ...

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep, 2021 FinancialContent

Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...

Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study
28 Sep, 2021 Yahoo! Finance

Ultragenyx (RARE) and GeneTx Biotherapeutics to start dosing in the phase I/II study on GTX-102 for treating pediatric patients with Angelman syndrome after the FDA removes its clinical hold on the same.

Ultragenyx Announces Crysvita® (burosumab) and UX143 (setrusumab) Data Presentations at Upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
27 Sep, 2021 FinancialContent
Ultragenyx Resumes Dosing Antisense Trial In Rare Neurogenetic Disorder
27 Sep, 2021 FinancialContent

TheFDA has removed the clinical holdonGeneTx Biotherapeutics LLCandUltragenyx Pharmaceutical ...

GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.
27 Sep, 2021 FinancialContent
Why Shares of Solid Biosciences Are Jumping Today
21 Sep, 2021 FinancialContent

Shareholders are expecting to finally get good news.

How The Pieces Add Up: SHE Headed For $116
17 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— SSGA Gender Diversity Index ETF (SHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $116.32 per unit.

Notable Ultragenyx Pharmaceutical Insider Trades $1.14 Million In Company Stock
10 Sep, 2021 Yahoo! Finance

Karah Parschauer, EVP And General Counsel at Ultragenyx Pharmaceutical (NASDAQ:RARE), made a large buy and sell of company shares on September 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 8, Karah Parschauer bought 7,336 Ultragenyx Pharmaceutical shares at a price of $54.50 per share, for a total of $399,812. They then sold their shares on the same day in the open market at a price of $100.65 to raise

Ultragenyx Pharmaceutical Larger Than S&P 500 Component HanesBrands
09 Sep, 2021 FinancialContent

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ultragenyx Pharmaceutical Inc (RARE) was identified as having a larger market cap than the smaller end of the S&P 500, for example HanesBrands Inc (HBI), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..

Ultragenyx to Present at Morgan Stanley Healthcare Conference
07 Sep, 2021 FinancialContent
MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults
07 Sep, 2021 FinancialContent

Ultragenyx Pharmaceutical Inc (RARE) is a NASDAQ Common Stock listed in , ,

970x250